Latest filingSep 03, 2026Most recent Form 4
KNSA
Kiniksa Pharmaceuticals International, plc
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$36.9M1 sells
Net open-market-$36.9M6 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period68transactions
- M · Option exercise · dominant48 · 71%
- A · Grants / awards12 · 18%
- F · Tax withholding6 · 9%
- G · Gifts1 · 1%
- S · Open-market sells1 · 1%
Activity by reported role
A joint filing can contribute to multiple roles90transactions
- Chief executive officer · dominant22 · 24%
- CHAIR22 · 24%
- CAO12 · 13%
- Chief financial officer11 · 12%
- CMO11 · 12%
- COO11 · 12%
- Director1 · 1%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (5)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typePatel Sanj KClass A Ordinary Share · Indirect · Held by The Patel Family Irrevocable Trust of 2025
86,165Sep 01, 2026
Patel Sanj KRestricted Share Unit · Direct
25,826Sep 01, 2026
Megna Michael RClass A Ordinary Share · Direct
29,062Sep 03, 2026
Megna Michael RRestricted Share Unit · Direct
4,725Sep 01, 2026
Moat RossClass A Ordinary Share · Direct
16,117Sep 01, 2026
Moat RossRestricted Share Unit · Direct
0Sep 01, 2026
Paolini John F.Restricted Share Unit · Direct
6,700Sep 01, 2026
Paolini John F.Class A Ordinary Share · Direct
69,922Sep 01, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 04 → Sep 04
LessMore
Top insiders
By absolute net value across the selected period- PK-$2.4M
- RM-$349.1k
- PF-$319.4k
- MR+$0
Recent filing activity
Most recent 12 transactions · color = transaction code- MOption exercise09/03$0SEC
- MOption exercise09/03$0SEC
- MOption exercise09/03$0SEC
- MOption exercise09/03$0SEC
- AGrant09/03$0SEC
- AGrant09/03$0SEC
- FTax withholding09/03-$34.9MSEC
- MOption exercise09/03—SEC
- MOption exercise09/03—SEC
- MOption exercise09/03—SEC
- MOption exercise09/03—SEC
- MOption exercise09/03$0SEC
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
KNSA transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| KNSA | Ragosa Mark | CFO | exercise | 2.69k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Ragosa Mark | CFO | exercise | 1.75k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Ragosa Mark | CFO | exercise | 1.59k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Ragosa Mark | CFO | exercise | 3.06k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Ragosa Mark | CFO | grant | 31.1k | $0 | A | — | 0.0% | 09/03 | 09/01 |
| KNSA | Ragosa Mark | CFO | grant | 7.80k | $0 | A | — | 0.0% | 09/03 | 09/01 |
| KNSA | Ragosa Mark | CFO | withholding | 4.40k | -$34.9M | F | — | 0.0% | 09/03 | 09/01 |
| KNSA | Ragosa Mark | CFO | exercise | 3.06k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Ragosa Mark | CFO | exercise | 1.59k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Ragosa Mark | CFO | exercise | 1.75k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Ragosa Mark | CFO | exercise | 2.69k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 9.99k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 6.48k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 6.23k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 8.60k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | grant | 120k | $0 | A | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | grant | 30.0k | $0 | A | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | withholding | 15.1k | -$120M | F | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 8.60k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 6.23k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 6.48k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 9.99k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 9.99k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 6.48k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 6.23k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 8.60k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | grant | 120k | $0 | A | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | grant | 30.0k | $0 | A | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | withholding | 15.1k | -$120M | F | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 8.60k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 6.23k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 6.48k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Patel Sanj K | CHAIRCEO | exercise | 9.99k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Paolini John F. | CMO | exercise | 2.49k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Paolini John F. | CMO | exercise | 1.62k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Paolini John F. | CMO | exercise | 1.75k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Paolini John F. | CMO | exercise | 2.45k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Paolini John F. | CMO | grant | 26.7k | $0 | A | — | 0.0% | 09/03 | 09/01 |
| KNSA | Paolini John F. | CMO | grant | 6.70k | $0 | A | — | 0.0% | 09/03 | 09/01 |
| KNSA | Paolini John F. | CMO | withholding | 4.02k | -$31.9M | F | — | 0.0% | 09/03 | 09/01 |
| KNSA | Paolini John F. | CMO | exercise | 2.45k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Paolini John F. | CMO | exercise | 1.75k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Paolini John F. | CMO | exercise | 1.62k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Paolini John F. | CMO | exercise | 2.49k | — | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Moat Ross | COO | exercise | 2.47k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Moat Ross | COO | exercise | 1.61k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Moat Ross | COO | exercise | 1.74k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Moat Ross | COO | exercise | 2.45k | $0 | M | — | 0.0% | 09/03 | 09/01 |
| KNSA | Moat Ross | COO | grant | 36.9k | $0 | A | — | 0.0% | 09/03 | 09/01 |
| KNSA | Moat Ross | COO | grant | 9.25k | $0 | A | — | 0.0% | 09/03 | 09/01 |
Kiniksa Pharmaceuticals International, plc Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Kiniksa Pharmaceuticals International, plc?
Ragosa Mark, Patel Sanj K, Paolini John F., Moat Ross, Megna Michael R, Quart Barry D.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Megna Michael R reported a sale on Sep 03, 2026 valued at $36.9M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $369,380.00. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.